Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis + lactobacillus acidophilus + enterococcus faecalis + bacillus cereus
- Development stage
- Phase 1
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A quadruple-strain probiotic medicinal product composed of *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. It is primarily indicated for the treatment of intestinal dysbiosis and associated symptoms such as acute or chronic diarrhea, constipation, and abdominal distension. The combination works synergistically: the anaerobic *Bifidobacterium* and *Lactobacillus* strains colonize the intestinal mucosa to form a biological barrier, while the aerobic *Bacillus cereus* and facultative anaerobic *Enterococcus faecalis* consume oxygen to create an environment conducive to the growth of beneficial anaerobic bacteria. It is widely used in China under the brand name Si Lian Kang, developed by Hangzhou Yuanda Biopharmaceutical.
- Brand names
- Si Lian KangSiliankang
- Other names
- Bifidobacterium tetragenous viable bacteriaQuadruple viable bacteriaBifidobacterium tetragenous viable bacteria tablets
Beyond the preview
Go deeper on bifidobacterium infantis + lactobacillus acidophilus + enterococcus faecalis + bacillus cereus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis + lactobacillus acidophilus + enterococcus faecalis + bacillus cereus.